Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Despite the relative success of chemotherapy for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), novel therapeutic agents are needed for refractory or relapsed patients. Targeted immunotherapy has emerged as a novel treatment option for these patients. Although unconjugated...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Chen, Xueyan, Soma, Lorinda A, Fromm, Jonathan R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2013
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3872218/
https://ncbi.nlm.nih.gov/pubmed/24379682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S39107
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller